Skip to main content

4 Result(s)

within Arvin Iracheta-Vellve Remove this filter Science, Humanities and Social Sciences, multidisciplinary Remove this filter

and

  1. Article

    Open Access

    The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

    Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases...

    Christina K. Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve… in Nature (2023)

    Download PDF (15912 KB) View Article

  2. No Access

    Article

    Targeting TBK1 to overcome resistance to cancer immunotherapy

    Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking1,2. Here we identify the innate immune kinase TANK-bin...

    Yi Sun, Or-yam Revach, Seth Anderson, Emily A. Kessler, Clara H. Wolfe… in Nature (2023)

  3. No Access

    Article

    Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

    Epigenetic dysregulation is a defining feature of tumorigenesis that is implicated in immune escape1,2. Here, to identify factors that modulate the immune sensitivity of cancer cells, we performed in vivo CRISPR–...

    Gabriel K. Griffin, **gyi Wu, Arvin Iracheta-Vellve, James C. Patti, Jeffrey Hsu… in Nature (2021)

  4. No Access

    Article

    Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

    Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of functi...

    Jeffrey J. Ishizuka, Robert T. Manguso, Collins K. Cheruiyot, Kevin Bi… in Nature (2019)